HCG vs Enclomiphene: Fertility Preservation on TRT

Fertility preservation is one of the most common reasons men seek alternatives or adjuncts to standard TRT protocols. Exogenous testosterone suppresses the HPG axis, reducing LH and FSH to near-zero, causing testicular atrophy and near-complete loss of spermatogenesis within 3-6 months. Two of the most commonly used interventions for preventing or reversing this are HCG (human chorionic gonadotropin) and enclomiphene.

HCG is a glycoprotein hormone that mimics LH. Administered as a subcutaneous injection, it binds LH/CG receptors on Leydig cells, directly stimulating intratesticular testosterone production without requiring pituitary involvement. This approach has decades of clinical evidence and is the current standard of care for fertility preservation in men on TRT.

Enclomiphene is the pure estrogen-antagonist isomer of clomiphene. It blocks estrogen receptors at the hypothalamus and pituitary, removing negative feedback and stimulating the pituitary to release both LH and FSH endogenously. This approach restores the full gonadotropin signal rather than bypassing it.

The key functional difference is FSH: HCG stimulates no FSH whatsoever, while enclomiphene raises both LH and FSH. FSH is essential for Sertoli cell function and full spermatogenesis, making this distinction critical for men with severely impaired sperm parameters.

Mechanism of action:

• HCG acts directly on the testes, bypassing the pituitary entirely. It mimics LH at the Leydig cell receptor. The pituitary sees the resulting testosterone rise and may further suppress its already-suppressed LH output.
• Enclomiphene acts at the pituitary by blocking estrogen receptor-mediated feedback suppression. It does not act directly on the testes and requires an intact, responsive pituitary-gonadal axis to work.

FSH stimulation:

• HCG: Zero FSH stimulation. The pituitary is bypassed, so no FSH is released. For men on TRT with severely suppressed spermatogenesis, HCG alone maintains intratesticular testosterone but cannot fully restore sperm production without FSH.
• Enclomiphene: Raises both LH and FSH. FSH drives Sertoli cell function, which is essential for spermatogenesis. This is why enclomiphene (and other SERMs) are considered superior for full spermatogenesis restoration.

Estradiol impact:

• HCG: Causes a disproportionate rise in estradiol through activation of intratesticular aromatase. At fertility-range doses, estradiol can peak at more than 4 times baseline within 24 hours.
• Enclomiphene: Results in a more proportionate estradiol rise secondary to increased testosterone production. Does not activate intratesticular aromatase to the same degree as HCG.

Route and frequency:

• HCG: Subcutaneous injection, typically 250-500 IU every other day or 500-1,500 IU twice to three times weekly.
• Enclomiphene: Oral tablet, 12.5-25 mg once daily. Significantly more convenient for most patients.

Compatibility with ongoing TRT:

• HCG: Compatible with concurrent TRT. Bypasses the testosterone-driven suppression of LH at the pituitary by acting directly on the testes.
• Enclomiphene: Not compatible with concurrent TRT at standard doses. Exogenous testosterone suppresses GnRH through androgen receptor pathways that enclomiphene cannot overcome. Best used after TRT cessation.

Choose HCG when:

• The patient is remaining on TRT and needs fertility preservation or testicular maintenance while on therapy
• Quick intratesticular testosterone restoration is needed (e.g., bridging the ester clearance period before PCT)
• Testicular atrophy is the primary concern rather than active fertility treatment
• The patient has a history of poor SERM response or has primary hypogonadism components

Choose enclomiphene when:

• The patient is discontinuing TRT and wants to restore natural testosterone production with fertility preserved
• FSH stimulation is required for spermatogenesis restoration (severely impaired sperm counts)
• The patient has experienced significant estrogenic side effects from HCG (elevated E2, water retention, gynecomastia)
• An oral, non-injection option is preferred
• SHBG is already elevated (enclomiphene does not further raise SHBG, unlike racemic clomiphene)

Consider combining both when:

• Severe suppression: profound testicular atrophy plus near-zero sperm counts on semen analysis
• Transition period: HCG to maintain testicular function during ester clearance, then transitioning to enclomiphene for HPTA restart
• Insufficient response to either agent alone at 6-8 weeks